Provided by Tiger Fintech (Singapore) Pte. Ltd.

Phathom Pharmaceuticals

4.03
-0.1950-4.62%
Post-market: 4.030.00000.00%19:40 EDT
Volume:956.15K
Turnover:3.94M
Market Cap:275.56M
PE:-0.76
High:4.30
Open:4.30
Low:4.02
Close:4.23
Loading ...

Phathom Pharmaceuticals price target lowered to $12 from $18 at Goldman Sachs

TIPRANKS
·
08 Mar

Phathom Pharmaceuticals price target lowered to $18 from $28 at Guggenheim

TIPRANKS
·
07 Mar

Analysts Offer Insights on Healthcare Companies: Phathom Pharmaceuticals (PHAT), Aziyo Biologics (ELUT) and IGM Biosciences (IGMS)

TIPRANKS
·
07 Mar

Phathom Pharmaceuticals: Strategic Positioning and Growth Potential in GERD Market Drives Buy Rating

TIPRANKS
·
07 Mar

Phathom Pharmaceuticals Full Year 2024 Earnings: Beats Expectations

Simply Wall St.
·
07 Mar

Phathom Pharmaceuticals Inc (PHAT) Q4 2024 Earnings Call Highlights: FDA Approval Boosts ...

GuruFocus.com
·
07 Mar

Phathom Pharmaceuticals Price Target Maintained With a $28.00/Share by Needham

Dow Jones
·
07 Mar

Phathom Pharmaceuticals: Strong Performance and Optimistic Outlook Amidst Patent Uncertainty

TIPRANKS
·
07 Mar

Phathom Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
06 Mar

Phathom Pharmaceuticals, Inc. (PHAT) Reports Q4 Loss, Tops Revenue Estimates

Zacks
·
06 Mar

Phathom Pharmaceuticals Q4 Adj $(0.79) Beats $(1.27) Estimate, Sales $29.66M Beat $24.91M Estimate

Benzinga
·
06 Mar

BRIEF-Phathom Pharmaceuticals Q4 Net Income USD -74.451 Million

Reuters
·
06 Mar

Phathom Pharmaceuticals Q4 Net Income USD -74.451 Million

THOMSON REUTERS
·
06 Mar

Phathom Pharmaceuticals Inc Qtrly Adj Shr Loss $0.79

THOMSON REUTERS
·
06 Mar

Phathom Pharmaceuticals Q4 Basic EPS USD -1.05

THOMSON REUTERS
·
06 Mar

Phathom Pharmaceuticals Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

GlobeNewswire
·
06 Mar

Craig-Hallum Reaffirms Their Buy Rating on Phathom Pharmaceuticals (PHAT)

TIPRANKS
·
06 Mar

Phathom Pharmaceuticals to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 6, 2025

GlobeNewswire
·
24 Feb

Cantor Fitzgerald Initiates Coverage on Phathom Pharmaceuticals With Overweight Rating, $23 Price Target

MT Newswires Live
·
14 Feb

Phathom Pharmaceuticals (PHAT) Gets a Buy from Stifel Nicolaus

TIPRANKS
·
10 Feb